Integrated Bioinformatic Analysis of Key Biomarkers and Signaling Pathways in Psoriasis

Suwei Tang  
Shanghai Skin Diseases Hospital

Ping Xu  
Shuguang Hospital

Shaoqiong Xie  
Shanghai Skin Diseases Hospital

Wencheng Jiang  
Shanghai Skin Diseases Hospital

Jiajing Lu  
Shanghai Skin Diseases Hospital

Yang Yang  
yy_lqg@sina.com  
: Shanghai Skin Diseases Hospital  
https://orcid.org/0000-0002-3590-6027

Research

Keywords: Psoriasis, Bioinformatic analysis, Differentially expressed genes, Protein-protein network, Molecular mechanism

Posted Date: April 23rd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-421570/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Psoriasis is a relatively common autoimmune inflammatory skin disease with a chronic etiology. The present study was designed to detect novel biomarkers and pathways associated with psoriasis incidence.

Methods: Differentially expressed genes (DEGs) associated with psoriasis in the Gene Expression Omnibus (GEO) database were identified, and their functional roles and interactions were then annotated and evaluated through GO, KEGG, and gene set variation (GSVA) analyses. In addition, the STRING database was leveraged to construct a protein-protein interaction (PPI) network, and key hub genes from this network were validated as being relevant through receiver operating characteristic (ROC) curve analyses of three additional GEO datasets. The CIBERSORT database was additionally used to assess the relationship between these gene expression-related findings and immune cell infiltration.

Results: In total 197 psoriasis-related DEGs were identified and found to primarily be associated with the NOD-like receptor, IL-17, and cytokine-cytokine receptor interaction signaling pathways. GSVA revealed significant differences between normal and lesional groups (P < 0.05), while PPI network analyses identified CXCL10 as the hub gene with the highest degree value, whereas IRF7, IFIT3, OAS1, GBP1, and ISG15 were promising candidate genes for the therapeutic treatment of psoriasis. ROC analyses confirmed that these 6 hub genes exhibited good diagnostic efficacy (AUC > 70%), and were predicted to be associated with increased sensitivity to 10 drugs (P < 0.01). The CIBERSORT database further predicted that these hub genes were associated with infiltration by 22 different immune cell types.

Conclusion: These results offer a robust foundation for future studies of the molecular basis for psoriasis, potentially guiding efforts to treat this common and disruptive disease.

Introduction

Psoriasis is a chronic autoimmune-mediated inflammatory skin condition that arises as a consequence of both environmental and genetic factors, leading affected patients to suffer from scaly erythema [1]. An estimated 2% of people in Europe and 0.47% of people in China are thought to suffer from psoriasis [2], and many of these patients suffer from poor quality of life [3]. While psoriasis is not a life-threatening condition, it can impose significant psychological and financial burdens on affected individuals. A number of therapies that can effectively treat psoriasis have been developed in recent years [4–5], including systemic retinoic acid delivery, immunosuppressant or cyclosporine treatment, and external glucocorticoid or retinoic acid application. However, some patients experience significant adverse reactions to these treatments. Owing to its complex and multifactorial etiology, psoriasis remains impossible to cure. It is thus vital that the molecular mechanism governing psoriasis development be clarified in order to guide more effective patient treatment.

Psoriasis exhibits polygenic patterns of inheritance and is primarily driven by T cells, with a range of factors stimulating excessive autoimmune activity in affected individuals. Recent studies of the
immunological basis for psoriasis have led to the development and commercialization of novel biological therapeutics targeting TNF-α, PDE-4, T cells, small cell signal transduction molecules, and VEGF. These inhibitors exhibit excellent clinical efficacy, but they are extremely expensive and have the potential to increase the risk of certain infections in treated patients, making them imperfect therapeutic agents.

Several different chemokine signaling pathways have been linked to the incidence of psoriasis [6–7]. These include several CXC family chemokines that can facilitate inflammatory T cell responses (CXCL10, CXCL16) and neutrophil responses (CXCL1, CXCL5) in psoriatic contexts, with these factors signaling through receptors including CXCR1 and CXCR2 in T cells, and CXCR3 and CXC6 in neutrophils [8]. Keratinocytes and other cells in the dermis of plaque psoriasis patients express CXCL10 and its receptor CXCR3, and CXCL10 levels in patient serum fall following patient treatment. While patients with newly diagnosed early-stage psoriasis often exhibit high CXCL10 levels, these levels tend to be lower in the serum of patients who have been suffering from this disease for longer periods of time [9]. Antibodies targeting CCL2 and CXCL10 can suppress the expression of these chemokines in psoriatic lesions, thereby reducing the severity of psoriasis as measured using PASI scores [10]. More research, however, is needed to fully understand the role of CXCL10 in psoriasis patients.

In recent decades, a range of microarray and sequencing technologies have been used to detect genetic and transcriptomic changes associated with particular disease states. These analyses have supported the identification of differentially expressed genes (DEGs) and functional pathways associated with the development and progression of psoriasis. However, individual microarray analyses have the potential to yield false-positive results that cannot be replicated. In addition, microarrays conducted using different platforms may exhibit result discordance owing to small sample sizes and to differences in the underlying platforms and statistical methods employed in individual studies. As such, further comprehensive analyses are necessary to ensure the reliable identification of robust diagnostic biomarkers and therapeutic targets capable of aiding in the treatment of psoriasis.

The present study was therefore designed to conduct an integrated analysis of three microarray datasets from the Gene Expression Omnibus (GEO) so as to identify key genes that were differentially expressed when comparing normal and psoriatic skin samples. Additional enrichment and network analyses were then performed to clarify the relationships between these DEGs and the progression of psoriasis. Together, our data provide a comprehensive framework that highlights the molecular mechanisms governing psoriasis pathogenesis, with CXCL10 in particular being identified as a promising biomarker of this debilitating disease.

**Materials And Methods**

**Data collection and preprocessing**

Raw gene expression profile data (cel files) for the GSE13355 (58 lesional skin samples, 64 normal skin samples), GSE30999 (82 lesional skin samples, 82 normal skin samples), and GSE106992 (125 lesional
skin samples, 67 normal skin samples) datasets were downloaded from the GEO database [11]. Hallmark gene sets were downloaded from the Molecular Signatures Database (MSigDB) [12]. Drug sensitivity data were downloaded from the cellminer Database [13].

**DEG identification**

DEGs were identified and plotted using R 3.6.2 with the Affy [14] and Limma packages [15]. DEGs were those meeting the following criteria: Adjusted P < 0.05, log |FC| > 1.0.

**Principal component analysis**

A multivariate principal component analysis (PCA) [16] was used to differentiate between samples. For this analysis, DEGs were treated as variables, and differences between healthy and psoriatic skin samples were identified.

**Functional enrichment analyses**

Gene Ontology (GO) [17] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [18] enrichment analyses were conducted with the R clusterProfiler package [19] in an effort to clarify the functional roles of identified DEGs in psoriasis. Enrichment was considered significant at a threshold of P < 0.05.

**Gene set variation analysis (GSVA)**

GSVA analyses evaluate pathway and biological process activity over a sample population in an unsupervised manner [20]. The “c2.cp.kegg.v6.2.symbols” and “h.all.v6.2.symbols” gene set files from the Molecular Signatures Database were used to conduct the GSVA analysis with the GSVA R package. P < 0.05 was the significance threshold for this analysis.

**Protein-protein interaction (PPI) network construction**

The STRING database (http://string-db.org)(v 10.0) [21] was used to construct a PPI network incorporating psoriasis-related DEGs with a combined interaction score > 0.4. The network was visualized with the open-source Cytoscape program (v 3.4.0) [22].

The plug-in Molecular Complex Detection (MCODE) (version 1.4.2) of Cytoscape is an APP for clustering a given network based on topology to find densely connected regions. The PPI networks were drawn using Cytoscape and the most significant module in the PPI networks was identified using MCODE. The criteria for selection were as follows: MCODE scores > 5, degree cut-off = 2, node score cut-off = 0.2, Max depth = 100 and k-score = 2.

**Hub genes selection and analysis**

The hub genes were selected with degrees ≥ 10. A network of the genes and their co-expression genes was analyzed using Cytoscape. The CytoHubba plugin in Cytoscape and molecular complex detection (MCODE) were employed to identify hub genes.

**ceRNA network construction**
Interactions between lncRNAs and miRNAs were predicted using miRcode [23]. StarBase was used to predict mRNA targets of miRNAs of interest [24], along with miRDB[25], and miRWalk[26]. Those interactions that were predicted by all three databases were the focus of interactions between miRNAs and psoriasis-related DEGs. A lncRNA/miRNA/mRNA ceRNA network was then constructed based on these predicted interactions, with the resultant network being visualized with the Cytoscape software[22].

ROC analysis

Receiver operating characteristic (ROC) curve analyses were used to assess the diagnostic performance of particular DEGs as a means of differentiating between psoriatic and normal samples based on area under the ROC curve (AUC) values [27]. These analyses were conducted with the R pROC package, with the value yielding the maximum sum of sensitivity and specificity serving as a cut-off value[28].

Drug Sensitivity Analysis

Drug sensitivity data were downloaded from GDSC, and the relationships between gene expression and putative psoriasis drug sensitivity were analyzed.

Immune infiltration analysis

The CIBERSORT database was used to evaluate the relationship between genes and immune cell infiltration profiles in normal and psoriatic samples in these three datasets [29]. The resultant data were visualized using bar charts, correlation charts, violin plots, and heatmaps. Correlations between hub genes and infiltrating immune cell populations in these three datasets were assessed, and samples were stratified into those that exhibit low or high levels of a given gene of interest based on the median expression value for that gene. Box plots were then used to visualize differences in the degree of immune cell infiltration by particular cell types between these high and low expression sample cohorts.

Statistical analysis

Data are means ± standard deviation, and were analyzed using R (v.3.6.2), with P < 0.05 as the significance threshold.

Results

Principal component analysis and distribution density mapping of psoriasis-related differentially expressed genes

We began by plotting distribution density maps for sample gene expression data from the GSE13355, GSE30999, and GSE106992 datasets (Fig. 1A-C), revealing similar expression profiles for both control and lesional samples in all cases, suggesting that sufficient data were available to permit variance analysis. Subsequent PCA revealed that control and lesional samples from these three datasets could be separated by the chosen DEGs, indicating that screened DEG expression patterns were specific and associated with psoriasis (Fig. 1D-F).
Differential gene expression analysis

Next, we identified DEGs in these three datasets using the R limma package, including 655, 849, and 286 DEGs in the GSE13355, GSE30999, and GSE106992 datasets, respectively. The resultant data were then subjected to heatmap and clustering analyses, which revealed clear and reliable differentiation between the control and psoriasis samples (Fig. 2A, C, E). Volcano plots additionally highlighted differences between groups with respect to DEG expression (Fig. 2B, D, F).

Functional enrichment analyses

Next, the 197 DEGs that were shared across these three datasets were next identified and used to conduct functional enrichment analyses (Fig. 3). GO terms significantly enriched for these genes included BPs such as response to virus, defense response to virus, antimicrobial humoral response, type 1 interferon signaling pathway, and cellular response to type 1 interferon (Table 1A). Enriched CCs included cornified envelope, specific granule lumen, tertiary granule lumen, secretory granule lumen, and cytoplasmic vesicle lumen (Table 1B). Enriched MFs included chemokine receptor binding, serine-type endopeptidase activity, serine-type peptidase activity, serine hydrolase activity, and chemokine activity (Table 1C). KEGG pathways revealed these DEGs to be enriched in 5 pathways, including the IL-17 signaling pathway (11 genes, hsa04657), the NOD-like receptor signaling pathway (14 genes, hsa04621), the Viral protein interaction with cytokine and cytokine receptor pathway (10 genes, hsa04061), the influenza A pathway (11 genes, hsa05164), and the cytokine-cytokine receptor interaction pathway (13 genes, hsa04060) (Table 1D). While the specific genes enriched in these pathways for each dataset were not identical, all three datasets were nonetheless enriched in the same pathway (Table 2).

GSVA analysis

The hallmark gene set was next selected as a reference set, after which a GSVA approach was used to assess differences in pathway enrichment between control and psoriatic samples in these three datasets. This analysis revealed that there were differences in the relative degree of pathway enrichment for different datasets, although the overall trends remained the same as above (Fig. 4).

Protein-protein interaction network

Next, interactions among these 197 DEGs were assessed by generating a PPI network with the STRING database (Table 3A). An interaction network diagram for these genes was additionally generated (Fig. 5A), and the MCODE plugin was used to select cluster 1 (Fig. 5B; Table 3B). The cytoHubba tool was then used to identify key hub genes within this cluster (Fig. 5C), leading to the identification of 10 key hub genes, with darker coloration corresponding to a higher degree value (Table 3C). A one-step interaction node for these 10 genes was then prepared (Fig. 5D). Those 6 genes that overlapped between the MCODE and cytoHubba hub gene analyses (CXCL10, IRF7, IFIT3, OAS1, GBP1, ISG15) were then identified as putative biomarkers of psoriasis (Table 4).

ceRNA network construction
The predictions made by the starBase, miRDB, and miRWalk databases were next integrated to identify putative miRNAs targeting these hub genes. StarBase was then further used to predict lncRNAs interacting with these miRNAs, facilitating the construction of a ceRNA network (Fig. 6).

**Assessment of hub gene diagnostic accuracy**

ROC curve analyses were next used to gauge the diagnostic accuracy of CXCL10, IRF7, IFIT3, OAS1, GBP1, and ISG15 (Fig. 7). The AUC values for these ROC curves were 0.959, 0.966, 1, and 0.98 for GSE13355 (Fig. 7A-F), while for GSE30999 they were 0.968, 0.963, 0.961, and 0.954 (Fig. 7G-L), and for GSE106992 they were 0.831, 0.835, 0.789, and 0.833 (Fig. 7M-R).

**Drug sensitivity analysis**

Next, drug sensitivity analyses were conducted for these six hub genes (Fig. 8). The results of these analyses suggested that certain drugs were negatively and positively correlated with the expression of these hub genes, with positive correlations indicating that a patient is more likely to be sensitive to a given drug if the corresponding gene is upregulated, and negative correlations indicating the opposite. In total, sensitivity to 10 different drugs was predicted to be increased (P < 0.05), including LDK-378, AP-26113, Alectinib, Lenvatinib, Tanespimycin, Pazopanib, Elesclomol, Estramustine, Abiraterone, Idelalisib, and Itraconazole.

**Immune cell infiltration analysis**

Lastly, we used the CIBERSORT algorithm to assess immune cell infiltration for each of these three datasets, assessing the immune cell composition of each sample, correlations between immune cell populations, and differences in immune cell levels between normal and diseased samples as represented using heatmaps and violin plots (Fig. 9).

We then conducted correlation analyses to examine the relationships between the hub genes identified above and immune cell infiltration in these three datasets, revealing significant differences in immune cell levels between samples with low and high levels of hub gene expression (Fig. 10).

**Discussion**

Psoriasis is an autoimmune inflammatory skin disease with a chronic etiology that impacts an estimated 0.96 per 1,000 people in Europe [30]. Psoriatic lesions can manifest as systemic or localized regions of scaly erythema and plaques, primarily in younger adults. There are four primary clinical types of psoriasis: ordinary, arthritis, pustular, and erythroderma, with the ordinary type accounting for over 99% of the total psoriasis disease burden. This disease generally exhibits a recurrent, chronic course that adversely impacts many aspects of individual physical and mental health, interfering with social interactions and other facets of daily life. In one survey, 79% of psoriasis patients reported that the disease had negatively impacted their lives, with 10% having contemplated suicide [31]. Current therapeutic targets associated with psoriasis include TNF-α, PDE-4, T cells, VEGF, and a range of signaling molecules, with many inhibitors targeting these pathways having been developed and marketed.
to date. Identifying novel biomarkers of psoriasis has the potential to improve patient quality of care and cost of treatment by facilitating the development of highly specific, inexpensive, and efficient treatments. Herein, we explored psoriasis-related gene expression patterns through a microarray-based bioinformatic analysis of three GEO gene expression profiles, leading to the identification of 197 DEGs associated with psoriasis incidence.

Identified DEGs were enriched for pathways including NOD-like receptor signaling, IL-17 signaling, cytokine-cytokine receptor interactions, Influenza A, viral protein interaction with cytokine and cytokine receptors, hepatitis C, drug metabolism-other enzymes, and biosynthesis of unsaturated fatty acids pathways. This analysis revealed a close relationship between IL-17 and psoriasis, consistent with prior reports highlighting a key role for this cytokine in psoriatic disease progression. IL-17 mRNA levels are elevated in psoriatic skin samples relative to normal skin [32]. Treatment of keratinocytes with IL-17 can further promote the upregulation of pro-inflammatory cytokines including IL-6 and IL-8, thereby potentially exacerbating psoriasis[33]. The topical application of the TLR7/8 ligand imiquimod can induce IL-17A and IL-17F expression and drive psoriasis-like dermatitis in mice [34]. Treatment with CsA and anti-TNF-a drugs can further decrease IL-17A, IFN-g, IL-23p19, and CCL20 levels in psoriatic lesions while improving psoriatic eruptions, [33.35-37], suggesting that IL-17A and other proinflammatory cytokines play key roles in psoriasis development.

In our PPI network analysis, we identified CXCL10 as having the highest degree value, while IRF7, IFIT3, OAS1, GBP1, and ISG15 were identified as key targets for the drug-based treatment of psoriasis. Targeting CXCL10 may thus be a viable approach to treating this debilitating disease. The upregulation of CXCL10 has been detected in many Th1 inflammatory diseases in humans [38]. Reductions in serum CXCL10 levels over time have been reported to be related to new-onset psoriatic arthritis in psoriasis patients [39]. We found that CXC family cytokines including CXCL1, CXCL9, and CXCL10 were primarily enriched in skin- and cytokine signaling-related GO and KEGG pathways, suggesting a potential role for these factors as regulators of psoriasis. Luster et al. previously highlighted the relationship between chemokines and inflammation, likely explaining their predicted role in psoriasis patients [40]. IRF7, IFIT3, OAS1, GBP1, and ISG15 were also identified as promising targets for the treatment of psoriasis. Raposo et al. detected significant upregulation of 16 different antiviral genes in lesional psoriatic skin, with ISG15 expression being increased more than two-fold [41], and others have similarly observed cutaneous upregulation of antiviral proteins in the context of psoriasis [42], potentially explaining why these patients rarely experience cutaneous viral infections. Psoriasis is also associated with keratinocyte expansion, and these cells may express high levels of antiviral genes. Immune cells also express high levels of these antiviral genes [41], potentially indicating robust immune cell and keratinocyte activity in this pathological context. Consistently, analyses of the CIBERSORT database suggested that these 6 hub genes were associated with infiltration by 22 different immune cell types. Together, these results offer new insights into biomarkers and pathways that may be targeted to more effectively treat psoriasis.

There are several limitations to this analysis. For one, integrated analyses of blood samples that were not conducted in the present study are required to more fully clarify the molecular mechanisms governing
psoriasis. Secondly, an individual microarray analysis has the potential to yield false-positive results that cannot be replicated. As such, it is essential that multiple individual datasets be integrated together to facilitate a more robust analysis of the genetic basis for psoriasis. Third, additional mechanistic experiments including western blotting, qPCR, and immunohistochemical assays will be required to clarify the functional importance of the hub genes identified in this study as regulators of psoriasis development and progression.

Conclusions

In summary, we conducted the present study to identify key genes likely to be involved in psoriasis development or progression. This led us to identify 197 key psoriasis-related DEGs, with CXCL10 representing a particularly promising biomarker worthy of future study as a sensitive indicator of psoriasis. However, further research will be needed to understand the biological role of this chemokine in patients with this condition, and to validate the results of this study so as to improve patient care.

Abbreviations

GEO: Gene Expression Omnibus; DEGs: Differentially expressed genes;

GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes;

PPI: Protein-protein interaction; IRF7: Interferon Regulatory Factor 7; IFIT3: Interferon Induced Protein With Tetratricopeptide Repeats 3; OAS1: Oligoadenylate Synthetase 1; GBP1: Guanylate Binding Protein 1

Declarations

Acknowledgements

Not applicable.

Authors’ contributions

ST and JL designed the current study, performed data analysis and wrote the manuscript. PX and YY performed the literature review regarding cytokines in psoriasis. JL and SX analyzed the data. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No.81872522, 82073429); Innovation Program of Shanghai Municipal Education Commission (No.2019-01-07-00-07-E00046).

Availability of data and materials
All data generated or analysed during this study are included in this published article.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' information**

a Department of Dermatology, Shanghai Skin Disease Hospital®School of medicine, Tongji University, Shanghai, 200443, China.  b Institute of Psoriasis®School of medicine, Tongji University, Shanghai, 200092, China.  c Department of Dermatology, Shuguang Hospital affiliated with Shanghai University

**References**

1. Nestle FO, Kaplan DH, Barker J. (2009). Psoriasis. New Engl J Med 361: 496-509.
2. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, Liu Y, Peng G, Zhou J, Xue S, Wang R, Tang Y, Meng X, Pei G, Bai Y, Liu Q, Li H, Zhang J. (2012). Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol 22: 663-667.
3. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. (2014). The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 134:1542-1551.
4. Jiang S, Hinchliffe TE, Wu T. (2015). Biomarkers of an auto immune skin disease-psoriasis. Genom Proteom Bioinf 13: 224-233.
5. Trowbridge RM, Pittelkow MR. (2014). Epigenetics in the pathogenesisand pathophysiology of psoriasis vulgaris. J Drugs Dermatol13:111-118.
6. Chen SC, de Groot M, Kinsley D, Laverty M, et al. (2010). Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 302 (2): 113-23.
7. Pohl D, Andrys C, Borska L, et al. (2009). CC and CXC chemokines patterns in psoriasis determined by protein array method were influenced by Goeckerman's therapy. Acta Medica 52 (1): 9-13.
8. Christopherson K 2nd, Hromas R. (2001). Chemokine regulation of normal and pathologic immune responses. Stem Cells 19 (5): 388-396.
9. Ferrari SM, Ruffilli I, Colaci M, et al. (2015). CXCL10 in psoriasis. Adv Med Sci 60 (2): 349-354.
10. Nedoszytko B, Sokolowska-Wojdylo M, Ruckemann-Dziurdzinska K, et al. (2014). Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol 31 (2): 84-91.
11. Barrett T., et al. (2013). NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41(Database issue): p. D991-5.
12. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst Dec 23;1(6):417-425.
13. Shankavaram, U.T., et al. (2009). CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10: p. 277.
14. Gautier L, Cope L, Bolstad BM, Irizarry RA. (2004). affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics Feb 12; 20(3): 307-15.
15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res Apr 20;43(7): e47.
16. Zhao W, Wang D, Zhao J, Zhao W. (2017). Bioinformatic analysis of retinal gene function and expression in diabetic rats. Exp Therapeutic Med 14(3):2485-92.
17. Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, Krueger JG, Salinger DH, Welcher AA and Martin DA. (2014). Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol 192: 3828-3836.
18. Bigler J, Rand HA, Kerkof K, Timour M and Russell CB. (2013). Cross-study homogeneity of psoriasis gene expression in skin across a large expression range. PLOS One 8: e52242, 2013.
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102(43): 15545-15550.
20. Hanzelmann S, Castelo R, Guinney J. (2013). GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14: 7.
21. Von Mering, C., et al. (2003). STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 31(1): p. 258-61.
22. Shannon, P., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11): p. 2498-504.
23. Jeggari A, Marks DS, Larsson E. (2012). miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 28(15):2062–2063.
24. Li, J.H., et al. (2014). starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42(Database issue): p. D92-7.
25. Chen, Y. and X. Wang. (2020). miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1): p. D127-D131.

26. Dweep, H., N. Gretz, and C. Sticht, miRWalk database for miRNA-target interactions. (2014). Methods Mol Biol 1182: p. 289-305.31.

27. Akobeng AK. (2007). Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatrica 96(5): 644-647.

28. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M. (2011). pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12(1): 77.

29. Chen, B., et al. (2018). Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol 1711: p. 243-259.

30. Valent F, Tullio A, Errichetti E, Stinco G. (2018). The epidemiology of psoriasis in an Italian area: population-based analysis of administrative data. G Ital Dermatol Venereol 29 (6): Epub ahead of print.

31. Krueger G, Koo J, Lebwohl M, et al. (2001). The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (3): 280-284.

32. Teunissen MBM, Koomen CW, De Waal Malefyt R, Wierenga EA, Bos JD. (1998). Interleukin-17 and interferon-c synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111: 645-649.

33. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008). Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128: 1207-1211.

34. Van der Fits L, Mourits S, Voerman JS et al. (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182: 5836-5845.

35. Zaba LC, Cardinale I, Gilleaudeau P et al. (2007). Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-3194.

36. Haider AS, Cohen J, Fei J et al. (2008). Insights into gene modulation by therapeutic TNF and IFN gamma antibodies: TNF regulates IFN gamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 128: 655–666.

37. Haider AS, Lowes MA, Su_arez-fari~nas M et al. (2008). Identification of cellular pathways of “type 1,” Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 80: 1913–1920.

38. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. (2002). IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168(7):3195-204.

39. Abji F, Lee K, Math M, Pollock R, Machhar R, Cook R, et al. (2020). Declining levels of serum CXCL10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker? Brit J Dermatol.
40. Epstein FH, Luster AD. (1998). Chemokines—chemotactic cytokines that mediate inflammation. New Engl J Med 338(7):436-45.

41. Raposo RA, Gupta R, Abdel-Mohsen M, Dimon M, Debbaneh M, Jiang W, et al. (2015). Antiviral gene expression in psoriasis. J Eur Acad Dermatol Venereol 29(10): 1951-7.

42. Wolk K, Witte K, Witte E et al. (2013). IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med 5: 204ra129.

Tables

Table I. GO and KEGG pathway enrichment analysis of DEGS in psoriasis samples.
| ID          | Description                                      | Count in gene set | pvalue       | p.adjust     |
|-------------|--------------------------------------------------|-------------------|--------------|--------------|
| GO:0009615  | response to virus                                | 24                | 4.14E-15     | 8.50E-12     |
| GO:0051607  | defense response to virus                        | 21                | 6.71E-15     | 8.50E-12     |
| GO:0019730  | antimicrobial humoral response                    | 16                | 2.57E-14     | 2.17E-11     |
| GO:0060337  | type I interferon signaling pathway              | 14                | 2.16E-13     | 1.09E-10     |
| GO:0071357  | cellular response to type I interferon           | 14                | 2.16E-13     | 1.09E-10     |
| GO:0001533  | cornified envelope                               | 10                | 3.25E-10     | 6.44E-08     |
| GO:0035580  | specific granule lumen                           | 7                 | 1.41E-06     | 0.000139     |
| GO:1904724  | tertiary granule lumen                           | 6                 | 9.99E-06     | 0.00066      |
| GO:0034774  | secretory granule lumen                          | 11                | 0.000167     | 0.00828      |
| GO:0060205  | cytoplasmic vesicle lumen                         | 11                | 0.000261     | 0.008832     |
| GO:0042379  | chemokine receptor binding                        | 11                | 4.60E-11     | 1.81E-08     |
| GO:0004252  | serine-type endopeptidase activity               | 14                | 7.18E-10     | 1.42E-07     |
| GO:0008236  | serine-type peptidase activity                   | 14                | 3.88E-09     | 5.06E-07     |
| GO:0017171  | serine hydrolase activity                         | 14                | 5.14E-09     | 5.06E-07     |
| GO:0008009  | chemokine activity                               | 8                 | 2.60E-08     | 1.85E-06     |
| hsa04657    | IL-17 signaling pathway                           | 11                | 2.41E-08     | 3.66E-06     |
| hsa04621    | NOD-like receptor signaling pathway              | 14                | 5.84E-08     | 4.44E-06     |
| hsa04061    | Viral protein interaction with cytokine and cytokine receptor | 10 | 4.86E-07 | 2.46E-05 |
| hsa05164    | Influenza A                                      | 11                | 1.02E-05     | 0.000388     |
| hsa04060 | Cytokine-cytokine receptor interaction | 13 | 8.77E-05 | 0.002666 |

Table II. KEGG pathway enrichment analysis of DEGS in the most significant module
| Pathway                                      | logFC   | P.Value   | adj.P.Val   |
|---------------------------------------------|---------|-----------|-------------|
| HALLMARK_INFLAMMATORY_RESPONSE              | 0.352579| 3.23E-26  | 1.61E-24    |
| HALLMARK_MYC_TARGETS_V2                    | 0.602905| 6.78E-26  | 1.69E-24    |
| HALLMARK_NOTCH_SIGNALING                    | -0.44874| 5.03E-25  | 8.39E-24    |
| HALLMARK_ALLOGRAFT_REJECTION                | 0.414567| 5.10E-24  | 6.38E-23    |
| HALLMARK_UV_RESPONSE_DN                    | -0.43353| 1.84E-23  | 1.84E-22    |
| HALLMARK_MTORC1_SIGNALING                   | 0.530295| 1.01E-20  | 8.45E-20    |
| HALLMARK_E2F_TARGETS                       | 0.523939| 1.35E-19  | 9.68E-19    |
| HALLMARK_INTERFERON_GAMMA_RESPONSE          | 0.379394| 5.10E-16  | 3.18E-15    |
| HALLMARK_COMPLEMENT                         | 0.240224| 2.41E-13  | 1.34E-12    |
| HALLMARK_MYOGENESIS                         | -0.26514| 3.02E-13  | 1.51E-12    |

| Pathway                                      | logFC   | P.Value   | adj.P.Val   |
|---------------------------------------------|---------|-----------|-------------|
| HALLMARK_MTORC1_SIGNALING                   | 0.474102| 2.18E-26  | 1.09E-24    |
| HALLMARK_MYOGENESIS                         | -0.31789| 1.96E-25  | 4.89E-24    |
| HALLMARK_E2F_TARGETS                        | 0.512633| 4.52E-25  | 7.53E-24    |
| HALLMARK_MYC_TARGETS_V2                     | 0.496877| 5.57E-22  | 6.96E-21    |
| HALLMARK_INTERFERON_GAMMA_RESPONSE          | 0.364591| 1.03E-20  | 1.03E-19    |
| HALLMARK_UV_RESPONSE_DN                     | -0.36363| 3.28E-20  | 2.73E-19    |
| HALLMARK_COMPLEMENT                         | 0.251523| 3.85E-18  | 2.75E-17    |
| HALLMARK_INFLAMMATORY_RESPONSE              | 0.272044| 3.23E-16  | 2.02E-15    |
| HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION  | -0.39572| 1.07E-15  | 5.97E-15    |
| HALLMARK_ALLOGRAFT_REJECTION                | 0.309652| 9.69E-15  | 4.84E-14    |

| Pathway                                      | logFC   | P.Value   | adj.P.Val   |
|---------------------------------------------|---------|-----------|-------------|
| HALLMARK_INTERFERON_GAMMA_RESPONSE          | 0.290468| 5.35E-13  | 2.68E-11    |
| HALLMARK_ALLOGRAFT_REJECTION                | 0.259119| 3.51E-11  | 8.78E-10    |
| HALLMARK_MYOGENESIS                         | -0.19898| 3.61E-10  | 6.02E-09    |
| Hallmark                  | Degree | p-value | q-value |
|--------------------------|--------|---------|---------|
| HALLMARK_MYC_TARGETS_V2  | 0.325852 | 1.53E-09 | 1.92E-08 |
| HALLMARK_COMPLEMENT      | 0.169069 | 2.66E-09 | 2.66E-08 |
| HALLMARK_UV_RESPONSE_DN | -0.23263 | 6.57E-09 | 5.36E-08 |
| HALLMARK_MTORC1_SIGNALING| 0.278927 | 7.50E-09 | 5.36E-08 |
| HALLMARK_NOTCH_SIGNALING | -0.21364 | 5.98E-08 | 3.74E-07 |
| HALLMARK_ADIPOGENESIS    | -0.17391 | 1.97E-07 | 9.86E-07 |
| HALLMARK_E2F_TARGETS    | 0.279246 | 1.97E-07 | 9.86E-07 |

Table III. Top 10 hub genes with DEGs degree from the PPI network.
### A

| node1 | node2 | combined_score |
|-------|-------|----------------|
| ABCA12 | TGM1  | 0.802          |
| ABCA12 | SPTLC2| 0.412          |
| ABCA12 | CNFN  | 0.401          |
| ABCA12 | TGM3  | 0.403          |
| ABCA12 | IL36RN| 0.459          |
| ABCA12 | PRSS27| 0.482          |
| ABCA12 | IVL   | 0.522          |
| ABCA12 | ALOX12B| 0.768        |
| ACOT1  | ACOT2 | 0.962          |
| ACOT1  | HAO2  | 0.46           |

### B

| MCODE_Cluster | MCODE_Score | name  |
|---------------|-------------|-------|
| Cluster 1     | 18          | HERC6 |
| Cluster 1     | 18          | IFI6  |
| Cluster 1     | 18          | OAS2  |
| Cluster 1     | 18          | RSAD2 |
| Cluster 1     | 18          | OAS1  |
| Cluster 1     | 18          | OAS3  |
| Cluster 1     | 18          | MX1   |
| Cluster 1     | 18          | CMPK2 |
| Cluster 1     | 18          | IFIT1 |
| Cluster 1     | 18          | ISG15 |

### C

| MCODE_Cluster | MCODE_Score | name  |
|---------------|-------------|-------|
| Cluster 2     | 8           | CCL20 |
| Cluster 1     | 18          | ISG15 |
| Cluster 2     | 8           | CXCL1 |
Table IV. Functional roles of 6 hub genes with degree $\geq 10$.

| Cluster | Degree | Gene   |
|---------|--------|--------|
| Cluster 2 | 10     | CXCL9  |
| Cluster 1 | 18     | GBP1   |
| Cluster 1 | 18     | OAS1   |
| Cluster 1 | 18     | IFIT3  |
| Cluster 1 | 18     | CXCL10 |
| Cluster 2 | 8      | CXCL8  |
| Cluster 1 | 18     | IRF7   |
| Gene symbol | Full name                                      | Function                                                                                                                                                                                                 | Pathway       |
|-------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| CXCL10      | C-X-C Motif Chemokine Ligand 10              | Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects | GO:0005102    |
|             |                                               |                                                                                                                                                                                                       | GO:0005125    |
|             |                                               |                                                                                                                                                                                                       | GO:0005515    |
|             |                                               |                                                                                                                                                                                                       | GO:0008009    |
|             |                                               |                                                                                                                                                                                                       | GO:0008201    |
| IRF7        | Interferon Regulatory Factor 7                | Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses.                                  | GO:0000978    |
|             |                                               |                                                                                                                                                                                                       | GO:0000981    |
|             |                                               |                                                                                                                                                                                                       | GO:0000987    |
|             |                                               |                                                                                                                                                                                                       | GO:0003677    |
|             |                                               |                                                                                                                                                                                                       | GO:0003700    |
| IFIT3       | Interferon Induced Protein With Tetratricopeptide Repeats 3 | IFN-induced antiviral protein which acts as an inhibitor of cellular as well as viral processes, cell migration, proliferation, signaling, and viral replication. Enhances MAVS-mediated host antiviral responses by serving as an adapter bridging TBK1 to MAVS which leads to the activation of TBK1 and phosphorylation of IRF3 and phosphorylated IRF3 translocates into nucleus to promote antiviral gene transcription | GO:0003674    |
|             |                                               |                                                                                                                                                                                                       | GO:0003723    |
|             |                                               |                                                                                                                                                                                                       | GO:0005515    |
|             |                                               |                                                                                                                                                                                                       | GO:0042802    |
| OAS1        | 2’-5’-Oligoadenylate Synthetase 1             | Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. | GO:0000166    |
|             |                                               |                                                                                                                                                                                                       | GO:0001730    |
|             |                                               |                                                                                                                                                                                                       | GO:0003723    |
|             |                                               |                                                                                                                                                                                                       | GO:0003725    |
|             |                                               |                                                                                                                                                                                                       | GO:0005515    |
| GBP1        | Guanylate Binding Protein 1                   | Hydrolyzes GTP to GMP in 2 consecutive cleavage reactions. Exhibits antiviral activity against influenza virus. Promotes oxidative killing and delivers antimicrobial peptides to autophagolysosomes, providing broad host protection against different pathogen classes. | GO:0000166    |
|             |                                               |                                                                                                                                                                                                       | GO:0003779    |
|             |                                               |                                                                                                                                                                                                       | GO:0003924    |
|             |                                               |                                                                                                                                                                                                       | GO:0005515    |
|             |                                               |                                                                                                                                                                                                       | GO:0005525    |
| ISG15       | ISG15 Ubiquitin Like Modifier                | Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein. | GO:0005178    |
|             |                                               |                                                                                                                                                                                                       | GO:0005515    |
|             |                                               |                                                                                                                                                                                                       | GO:0031386    |
Figures

Figure 1

The distribution density map and the principal component analysis of the three datasets. (A) GSE13355 distribution density map. (B) GSE30999 distribution density map. (C) GSE106992 distribution density map. (D) GSE13355 principal component analysis. (E) GSE30999 principal component analysis. (F) GSE106992 principal component analysis.
DEGs identified by microarray assay between psoriatic and NN skin. (A, C, E) Heat maps of DEGs in GSE13355, GSE30999 and GSE106992. (D, E, F) Volcano plots of DEGs in GSE13355, GSE30999 and GSE106992. Volcano plots show the -log10Q-values against logFC for DEGs in the skin, in which the green, red, and gray points represent down-expressed, upexpressed, and not DEGs, respectively.
Figure 3

GO and KEGG analysis of 197 DEGs. (A-C) Chord plot indicates the relationship between genes and KEGG pathways in GSE13355. (D) Significantly enriched pathway terms of DEGs in GSE13355. (E-G) Chord plot indicates the relationship between genes and KEGG pathways in GSE30999. (H) Significantly enriched pathway terms of DEGs in GSE30999. (I-K) Chord plot indicates the relationship between genes and KEGG pathways in GSE106992. (L) Significantly enriched pathway terms of DEGs in GSE106992.
Gene set variation analysis (GSVA) of hallmark genes in three datasets. (A) GSVA in GSE13355 dataset. (B) GSVA in GSE30999 dataset. (C) GSVA in GSE106992 dataset.

PPI network and the most significant module of DEGs. (A) The PPI network of DEGs was constructed using Cytoscape. (B) The most significant module was obtained from PPI network with 20 nodes. Upregulated genes are marked in light red; downregulated genes are marked in light blue. (C) Top 10 hub genes with DEGs degree from the PPI network. (D) Hub genes and their co-expression genes were analyzed using cytoHubba.
Figure 6

Construction of ceRNA network in 6 hub genes. (A) CeRNA network in CXCL10. (B) CeRNA network in IRF7. (C) CeRNA network in IFIT3. (D) CeRNA network in OAS1. (E) CeRNA network in GBPI. (F) CeRNA network in ISG15.
Figure 7

ROC curve analysis of 6 hub genes in three datasets. (A-F) The areas under the ROC curves were 0.95, 0.959, 0.966, 1, 0.98 and 0.989 for GSE13355. (G-L) The areas under the ROC curves were 0.92, 0.968, 0.963, 0.961, 0.954 and 0.977 for GSE30999. (M-R) The areas under the ROC curves were 0.76, 0.831, 0.835, 0.789, 0.833 and 0.795 for GSE106992.
Figure 8

Drug sensitivity analysis of 6 hub genes. The sensitivity to 10 drugs were increased (P ≤ 0.05), including LDK-378, AP-26113, Alectinib, Lenvatinib, Tanespimycin, Pazopanib, Elesclomol, Estramustine, Abiraterone, Idelalisib and Itraconazole. *P ≤ 0.05; **P ≤ 0.01.
**Figure 9**

Immune infiltration analysis in three datasets. (A, E, I) Immune cell analysis of GSE13355, GSE30999 and GSE 106992 was shown in the bar graph. (B, F, G) The correlation of the expression of immune cells in GSE13355, GSE30999 and GSE 106992 was analyzed. (C, G, K) The difference in the expression of immune cells between disease and normal samples was analyzed, as shown in the heat map. (D, H, L) The difference in the expression of immune cells between disease and normal samples was analyzed, as shown in the violin plot.

**Figure 10**
Correlation analysis of Immune infiltration of 6 hub genes. (A-F) Correlation analysis of immune infiltration of 6 hub genes in GSE13355. (G-L) Correlation analysis of immune infiltration of 6 hub genes in GSE30999. (M-R) Correlation analysis of immune infiltration of 6 hub genes in GSE106992.